GYN ONC (Gynecologic oncology)
NRG – GY026 at https://www.clinicaltrials.gov/study/NCT05256225
A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-OYSK (Herceptin Hylecta™) or pertuzumab, trastuzumab, and hyaluronidase-ZZXF (Phesgo®) in HER2 positive, Stage I-IV endometrial serous carcinoma or carcinosarcoma
Cancer Type: Endometrial serous carcinoma or carcinosarcoma, HER2+
Principal Investigator: Dr. Deborah Brandt
Please contact Clinical Trials Office for more details: 561-263-5791
-
Jupiter Medical CenterWe want to help you! If you have questions about our services and what we can offer you and your loved ones, please reach out.
